Aller au contenu principal
Accès ouvert déclaré 2023 preprint

Creating the Pick’s disease International Consortium: Association study of MAPT H2 haplotype with risk of Pick’s disease

2Citations signalées — pas une note de qualité
91Institutions déclarées
15Pays d’affiliation déclarés

Résumé fourni par la source

Abstract Background Pick’s disease (PiD) is a rare and predominantly sporadic form of frontotemporal dementia that is classified as a primary tauopathy. PiD is pathologically defined by argyrophilic inclusion Pick bodies and ballooned neurons in the frontal and temporal brain lobes. PiD is characterised by the presence of Pick bodies which are formed from aggregated, hyperphosphorylated, 3-repeat tau proteins, encoded by the MAPT gene. The MAPT H2 haplotype has consistently been associated with a decreased disease risk of the 4-repeat tauopathies of progressive supranuclear palsy and corticobasal degeneration, however its role in susceptibility to PiD is unclear. The primary aim of this study was to evaluate the association between MAPT H2 and risk of PiD. Methods We established the Pick’s disease International Consortium (PIC) and collected 338 (60.7% male) pathologically confirmed PiD brains from 39 sites worldwide. 1,312 neurologically healthy clinical controls were recruited from Mayo Clinic Jacksonville, FL (N=881) or Rochester, MN (N=431). For the primary analysis, subjects were directly genotyped for MAPT H1-H2 haplotype-defining variant rs8070723. In secondary analysis, we genotyped and constructed the six-variant MAPT H1 subhaplotypes (rs1467967, rs242557, rs3785883, rs2471738, rs8070723, and rs7521). Findings Our primary analysis found that the MAPT H2 haplotype was associated with increased risk of PiD (OR: 1.35, 95% CI: 1.12-1.64 P=0.002). In secondary analysis involving H1 subhaplotypes, a protective association with PiD was observed for the H1f haplotype (0.0% vs. 1.2%, P=0.049), with a similar trend noted for H1b (OR: 0.76, 95% CI: 0.58-1.00, P=0.051). The 4-repeat tauopathy risk haplotype MAPT H1c was not associated with PiD susceptibility (OR: 0.93, 95% CI: 0.70-1.25, P=0.65). Interpretation The PIC represents the first opportunity to perform relatively large-scale studies to enhance our understanding of the pathobiology of PiD. This study demonstrates that in contrast to its protective role in 4R tauopathies, the MAPT H2 haplotype is associated with an increased risk of PiD. This finding is critical in directing isoform-related therapeutics for tauopathies. Funding See funding section

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
Creating the Pick’s disease International Consortium: Association study of <i>MAPT</i> H2 haplotype with risk of Pick’s disease
Date Crossref
24/04/2023
Éditeur
openRxiv
Type
posted-content

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Mayo Clinic in FloridaUK Dementia Research InstituteNational Hospital for Neurology and NeurosurgeryUniversity College LondonHong Kong University of Science and TechnologyHong Kong Science and Technology Parks CorporationMayo ClinicWinnMedMount Sinai Medical CenterUniversity of Kansas Medical CenterMayo Clinic in ArizonaUniversity of California, San FranciscoUniversity Memory and Aging CenterUniversity of PennsylvaniaHarvard UniversityMassachusetts General HospitalHospital Clínic de BarcelonaBanc de Sang i TeixitsUniversitat de BarcelonaConsorci Institut D'Investigacions Biomediques August Pi I SunyerMedical University of ViennaHospital de PalamósBellvitge University HospitalInstitut d'Investigació Biomédica de BellvitgeHospital de MataróHospital Universitari de Santa MariaInstituto de Investigación Biomédica de LleidaNorthwestern UniversityJohns Hopkins UniversityJohns Hopkins MedicineUniversity of FloridaIndiana University School of MedicineIndiana University – Purdue University IndianapolisSalford Royal NHS Foundation TrustUniversity of ManchesterManchester Academic Health Science CentreSalford Royal HospitalCambridge University Hospitals NHS Foundation TrustMRC Cognition and Brain Sciences UnitMedical Research CouncilBanner Sun Health Research InstituteColumbia UniversitySunnybrook Health Science CentreHealth Sciences CentreSunnybrook Research InstituteKing's College LondonKing's College Hospital NHS Foundation TrustThe University of SydneyEmory UniversityAlzheimer’s Disease Neuroimaging InitiativeLudwig-Maximilians-Universität MünchenNewcastle UniversityThe University of Texas Southwestern Medical CenterDouglas CollegeDouglas Mental Health University InstituteUniversity of AntwerpGhent University HospitalAntwerp University HospitalVIB-UAntwerp Center for Molecular NeurologyInstitute of NeurobiologyAssistance Publique – Hôpitaux de ParisInstitut du CerveauCentre National de la Recherche ScientifiqueInsermSorbonne UniversitéUniversity of British ColumbiaFlorey Institute of Neuroscience and Mental HealthHouston MethodistCornell UniversityWeill Cornell MedicineDuke Medical CenterDuke University HospitalKarolinska University HospitalKarolinska InstitutetBrentwood Biomedical Research InstituteVA Sepulveda Ambulatory Care CenterUniversity Health NetworkUniversity of TorontoOccupational Cancer Research CentreOntario Brain InstituteFondazione IRCCS Istituto Neurologico Carlo BestaDon Carlo Gnocchi FoundationUniversity of FlorenceGerman Center for Neurodegenerative DiseasesUniversity Children's Hospital TübingenWestern UniversityLondon Health Sciences CentreNational Institutes of HealthNational Institute on AgingUniversity of MinhoNano and Advanced Materials Institute

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Neurogenetic and Muscular Disorders ResearchRNA modifications and cancerRNA regulation and disease

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.